The disadvantages of peptide cancer vaccines are as follows: relatively poor immunogenicity, tumor heterogeneity, inappropriate adjuvants, antigen loss, low MHC expression, lack of T-cell infiltration in the tumor tissue, and inducing immune suppression through T-cell dysfunction [43,51,54]. This evidence concerns the gene HLA-C and neoplasm.